We sought to establish a rapid and reliable RT-PCR approach for detection and quantification of BCR-ABL fusion transcripts using the LightCycler technology. This device combines rapid thermocycling with online detection of PCR product formation and is based on the fluorescence resonance energy transfer (FRET) between two adjacent hybridization probes carrying donor and acceptor fluorophores. A pair of probes was designed that was complementary to ABL exon 3, thus enabling detection of all known BCR-ABL variants and also normal ABL as an internal control. Conditions were established to amplify less than 10 target molecules/reaction and to detect one CML cell in 10 5 cells from healthy donors. To determine the utility of the assay, we quantified BCR-ABL and ABL transcripts in 254 samples (222 peripheral blood, 32 bone marrow) from 120 patients with CML after therapy with IFN-␣ (n ‫؍‬ 219), allogeneic BMT (n ‫؍‬ 17), chemotherapy (n ‫؍‬ 11), or at diagnosis (n ‫؍‬ 7). The level of residual disease in the 245 BCR-ABL positive specimens was expressed as the ratio of BCR-ABL/ABL. This ratio was compared to results obtained by three established methods from contemporaneous specimens. A highly significant correlation was seen between the BCR-ABL/ABL ratios determined by the LightCycler and (1) the BCR-ABL/ABL ratios obtained by nested competitive RT-PCR (n ‫؍‬ 201, r ‫؍‬ 0.90, P Ͻ 0.0001); (2) the proportion of Philadelphia chromosome positive metaphases determined by cytogenetics (n ‫؍‬ 81, P Ͻ 0.0001); and (3) the BCR ratio determined by Southern blot analysis (n ‫؍‬ 122, P Ͻ 0.0001). We conclude that real-time PCR with hybridization probes is a reliable and sensitive method to monitor CML patients after therapy. The major advantages of the methodology are (1) amplification and product analysis are performed in the same reaction vessel, avoiding the risk of contamination; (2) the results are standardized by the quantification of housekeeping genes; and (3) the complete PCR analysis takes less than 60 min.
Introduction
In many ways, chronic myelogenous leukemia (CML) serves as a paradigm for the utility of molecular methods to diagnose malignancy or to monitor patient response to therapy. 1 Several approaches have been introduced that can specifically detect the t(9;22) or its products, such as fluorescent in situ hybridization, Southern blotting, Western blotting, and RT-PCR (for reviews, see . Of these, RT-PCR for BCR-ABL mRNA is by far the most sensitive and consequently has received the most attention in the context of minimal residual disease.
Since non-quantitative RT-PCR analysis gives only limited information, several groups have developed quantitative or semi-quantitative RT-PCR assays that enable the kinetics of residual BCR-ABL transcripts to be monitored over time in patients after allogeneic stem cell transplantation or interferon-␣ (IFN-␣) therapy. Currently, the most common method to quantify BCR-ABL transcripts is by competitive PCR. Although this method has been established in a number of laboratories, it is cumbersome and requires large numbers of individual amplification reactions to be performed for each data point.
Recently, however, novel real-time PCR procedures have been developed that promise to simplify existing protocols. A procedure for quantification of BCR-ABL mRNA using the TaqMan system has been described. 5, 6 Here we have established an alternative real-time RT-PCR approach for detection and quantification of BCR-ABL fusion transcripts using the new LightCycler technology, 7, 8 which combines rapid thermocycling with online fluorescence detection of PCR product formation as it occurs. Fluorescence monitoring of PCR amplification is based on the concept of fluorescence resonance energy transfer (FRET) between two adjacent dyes. Excitation of a donor fluorophore with an emission spectrum that overlaps the excitation spectrum of an acceptor fluorophore results in nonradioactive energy transfer to the acceptor. Fluorescein is used as a donor fluorophore, LC Red640 (Roche Diagnostics, Mannheim, Germany) as the acceptor fluorophore. Once conditions are established, the amount of fluorescence resulting from the two probes is proportional to the amount of PCR product. We demonstrate that hybridization probes in combination with the LightCycler enables rapid and robust quantification of BCR-ABL and control transcripts in clinical specimens.
Patients and methods

Patients and samples
A total of 254 (222 peripheral blood (PB) and 32 bone marrow (BM) samples from 120 CML patients (76 male; 44 female) were analyzed. Between one and nine samples were investigated from each patient during the course of their disease. Informed consent was obtained as required by the Declaration of Helsinki. At diagnosis, 117 patients were Ph-positive and three Ph-negative/BCR-ABL-positive. 219 samples were obtained on or after therapy with IFN-␣, 17 after allogeneic BMT, 11 after chemotherapy, and seven at diagnosis. Ͼ94% Ph+ metaphases. 10 A minimum of 10 metaphases were analyzed. A total of 81 RT-PCR results obtained by the LightCycler were available for comparison with contemporaneous (±3 months) cytogenetic analyses.
Southern blot analysis
Southern blotting was performed as reported.
11,12 DNA obtained from PB or BM was digested with BglII, EcoRI, BamHI, XbaI, and/or HindIII, electrophoresed on a 0.7% agarose gel, blotted, and hybridized to the 2 kb BglII/HindIII (5ЈM-bcr) and 1.2 kb HindIII/BglII (3ЈM-bcr) probes. Response was expressed as complete (BCR ratio 0%), partial (1-24%), minor (25-49%) and none (у50%). 12 
RNA extraction, cDNA synthesis
Total leukocyte RNA was extracted from 10 to 20 ml of PB and/or from 1 to 5 ml of BM aspirate after lysis of red blood cells. 13 Samples were processed as soon as possible after aspiration, although some spent 1 to 3 days in transit. RNA extraction was performed by CsCl gradient centrifugation 13 or by commercially available extraction kits. RNA was reverse transcribed using random hexamer priming and MMLV reverse transcriptase as described. 13 cDNAs were stored at −20°C.
Competitive PCR
The type of BCR-ABL transcript was determined by multiplex PCR 14 or nested PCR as described. 13, 15 An estimate of the number of BCR-ABL transcripts and total ABL transcripts as an internal standard was made by a competitive PCR titration assay. [15] [16] [17] The final result of quantification by competitive PCR was expressed as the ratio between BCR-ABL and ABL transcripts in percentage.
Real-time quantitative PCR
PCR was performed using 2 l mastermix (LightCycler DNA Master Hybridization Probes; Roche Diagnostics, Mannheim, Germany, containing buffer, dATP, dCTP, dGTP, dUTP, and Taq polymerase); 4 mm MgCl 2 , 0.25 m of each 3Ј and 5Ј fluorescent hybridization probes (TIB MolBiol, Berlin, Germany), 0.5 m of each 3Ј and 5Ј oligonucleotide primer (highly purified salt free (HPSF) grade, MWG, Ebersberg, Germany), 1 U heat labile uracil DNA glycosylase (UDG, Roche Diagnostics), 2 l cDNA, and water to a final volume of 20 l. Prior to amplification, mixes were incubated for 5 min at room temperature to allow degradation of specific contaminating PCR products from previous amplifications by UDG. Heat labile UDG was deactivated by an initial denaturation step of 1 min at 95°C. Amplification occurred in a threestep cycle procedure (denaturation, 95°C, 1 s, ramp rate 20°C/s; annealing 64°C, 10 s, ramp rate 20°C/s; and extension 72°C, 26 s, ramp rate 2°C/s) for 45 cycles. The following primers were used for amplification: b2a2, b3a2, b2a3, or b3a3 BCR-ABL, primers B2A and NA4-; e1a2 BCR-ABL, primers PE1+ and NA4−; ABL, primers A2N and NA4-; glucose-6-phosphate dehydrogenase (G6PD), primers G6PD1 and G6PD2 ( Figure 1 , Table 1 ). Sequences of the probes have been selected empirically using the recommendations of the manufacturer. Amplification, fluorescence detection, and post-processing calculations were performed using the LightCycler apparatus (Roche Diagnostics).
5Ј Hybridization probes were labeled with fluorescein, 3Ј probes with LC Red640. Fluorescein is excited by blue light (470 nm) and emits green light at a slightly longer wave length. If the two dyes are in close proximity (ie after cohybridization of the two oligonucleotide probes to the target sequence), the energy emitted by the fluorescein excites the LC Red640 which then emits red fluorescent light (640 nm). Fluorescence was measured after each annealing step and expressed as the ratio between fluorescence at 640 nm (designated F2) and at 530 nm (background, designated F1).
The fluorescence signal was plotted against the cycle number for all samples and external standards. These standards consisted of serial dilutions (10 1 to 10 7 molecules per reaction) of plasmids pGD210 (b3a2 BCR-ABL ), pB190 (e1a2 BCR-ABL ), and pGdBBX (G6PD). Initially, the crossover point was determined for each standard dilution, ie the point at which the signal rose above the background level. The higher the initial number of starting molecules, the earlier the signal appears above the background ( Figure 2 ). A standard curve for each run was constructed by plotting the crossover point against the log (number of standard molecules). The number of target molecules in each sample was then calculated automatically by reference to this curve. Results were expressed initially as the number of target molecules/2 l cDNA. Normalized levels of disease were calculated as the ratios (expressed as percentage) between BCR-ABL and ABL and between BCR-ABL and G6PD transcripts in 2 l of cDNA.
Some amplification products performed in the LightCycler were checked by electrophoresis on 1.5% ethidium bromide stained agarose gels. The estimated size of the amplified fragments matched the calculated size 18, 19 for b3a2 BCR-ABL (671 bp), b2a2 BCR-ABL (596 bp), b3a3 BCR-ABL (497 bp), b2a3 BCR-ABL (422 bp), e1a2 BCR-ABL (540 bp), ABL (386 bp), and G6PD (343 bp) in all cases.
Statistical analysis
The ratios BCR-ABL/ABL and BCR-ABL/G6PD were compared with the proportion of Ph+ metaphases for all samples that had contemporaneous cytogenetic analyses. The comparison of the BCR-ABL/ABL and BCR-ABL/G6PD ratios between the response groups determined by cytogenetics or Southern blot analysis was made using the Kruskal-Wallis test. The correlation between ABL and G6PD transcript numbers as internal controls, between the ratios BCR-ABL/ABL derived from competitive PCR vs real-time PCR, and between paired results from PB and BM was evaluated using Spearman's rank correlation coefficient. The equation of the regression line of ABL and G6PD transcript numbers and results from PB and BM were calculated by least-squares analysis. Results from contemporaneous PB and BM samples were compared by the paired Student's t-test.
Results
Sensitivity of real-time PCR
In repeated tests, we could reliably amplify 10 b3a2 or e1a2 BCR-ABL, 10 ABL, and 10 G6PD molecules per reaction. To Schematic map of the amplification and detection of BCR-ABL and ABL transcripts. Specific primer pairs were used to amplify various types of BCR-ABL and ABL transcripts. The detection format was uniform using a pair of adjacent fluorescent labeled hybridization probes to ABL exon 3. Hybridization probes a3-3ЈHP 5Ј LC Red 640-AATGGGGAATGGTGTGAAGCCCAAA-P ABL exon 3 a3-5ЈHP 5Ј TGAAAAGCTCCGGGTCTTAGGCTATAATCA-F ABL exon 3 G6PD-3ЈHP 5Ј LC Red 640-CAAATCTCAGCACCATGAGGTTCTGCAC-P G6PD exon 7/6 G6PD-5ЈHP 5Ј GTTCCAGATGGGGCCGAAGATCCTGTTG-F G6PD exon 7 F, fluorescein; P, phosphate; LC Red 640, LightCycler fluorescence dye 640. calculate the maximum sensitivity, serial dilutions of 5, 50, 500, and 5000 myeloid PB cells from a b3a2 BCR-ABL positive CML patient at diagnosis in 5 × 10 7 leukocytes from a healthy donor were processed and analyzed. We routinely achieved a sensitivity of 10 
Patient samples: qualitative nested RT-PCR
All 254 cDNA samples were BCR-ABL positive by conventional nested PCR. 64 patients expressed b3a2, 40 b2a2, 13 both b3a2 and b2a2, and one each b3a3, b2a3, and e1a2 BCR-ABL transcripts.
Patient samples: real time PCR
Of the 254 samples that were BCR-ABL positive by nested PCR, 245 were also BCR-ABL positive by the LightCycler. Between 10 and 3 700 000 (median 10 000) BCR-ABL transcripts were detected. All 254 samples were positive for total ABL transcripts; between 150 and 11 600 000 (median 540 000) ABL transcripts were detected (Table 2) . Nine BCR-ABL negative samples showed ABL transcript levels of 150 to 1 390 000 (median 119 000).
Comparison of ABL and G6PD transcript numbers as internal controls
In 249 samples, G6PD transcripts were quantified as a second internal standard. All samples were positive, between 300 and 7 000 000 (median 630 000) G6PD transcripts were detected ( Table 2 ). The number of G6PD transcripts was at a median of 1.5 times higher than the number of ABL transcripts. G6PD and ABL transcript numbers correlated with r = 0.74 (P Ͻ 0.0001; Figure 3 ).
Comparison of real-time PCR and competitive PCR
In 201 cDNA samples the ratio BCR-ABL/ABL was determined by nested competitive PCR which compared well with the Comparison of the quantification of total ABL and G6PD transcripts as internal controls in 249 consecutive samples. The transcript numbers of both genes correlate with r = 0.74, P Ͻ 0.0001. same ratio determined by real time PCR (r = 0.90, P Ͻ 0.0001, Figure 4 ). Five of nine samples that were negative on the LightCycler but positive by nested RT-PCR were tested by competitive PCR and found to be positive at a median BCR-ABL transcript level of 0.036% (range 0.0034 to 0.9%).
Comparison of real-time PCR and cytogenetics
Contemporaneous metaphase cytogenetic results were available for 81 samples investigated by real-time PCR. They showed a complete response (n = 17), partial response (n = 20), minor response (n = 15), and nonresponse (n = 29) and 
Comparison of real-time PCR and Southern blot analysis
The BCR ratio as determined by quantitative Southern blot analysis in 122 DNA samples extracted from the same PB or BM samples from which RNA was extracted for PCR analysis revealed a complete response (n = 50), a partial response (n = 30), a minor response (n = 14), and a nonresponse (n = 28) and correlated with the ratios BCR-ABL/ABL as determined by real time PCR (P Ͻ 0.0001, Figure 6 ).
BCR-ABL levels in PB and BM
In eight cases, PB and BM samples obtained on the same day were available for comparison. The ratios BCR-ABL/ABL and BCR-ABL/G6PD in the two tissues were not significantly different. The ratios BCR-ABL/ABL (r = 0.90, P = 0.0046) and BCR-ABL/G6PD (r = 0.98, P = 0.0004) correlated well between PB and BM samples (Figure 7 ).
Discussion
The assessment of the proportion of malignant BM or PB cells is an important prognostic indicator for CML patients after therapy. Cytogenetic analysis is still the standard technique for defining the response of patients to treatment, but this technique suffers from serious limitations. Bone marrow metaphases are required and aspiration and cultivation of proliferating cells is not always sufficient. Furthermore, this technique is relatively insensitive since typically a maximum number of only 20-50 metaphases are analyzed. We and others have Ratios BCR-ABL/ABL (a) and BCR-ABL/G6PD (b) derived from real-time PCR according to contemporaneous cytogenetic response. The ratios BCR-ABL/ABL and BCR-ABL/G6PD are significantly different between complete, partial, minor and nonresponders (P Ͻ 0.0001).
Figure 6
Comparison of the ratio BCR-ABL/ABL derived from realtime PCR vs BCR ratio derived from Southern blot analysis of genomic DNA from the same PB or BM samples. The ratios BCR-ABL/ABL are significantly different between the Southern blot response groups (P Ͻ 0.0001).
previously demonstrated the advantages of quantitative PCR techniques for monitoring CML patients during or after treatment. 2 Competitive PCR results correlate well with the cytogenetic response in individuals treated with IFN-␣ 17 and moreover, the actual levels of detectable residual disease in Correlation of the log 10 ratio BCR-ABL/ABL (a) and BCR-ABL/G6PD (b) obtained from eight pairs of contemporaneous PB and BM samples. The coefficient of regression is r = 0.90 (P = 0.0046) for the ratios BCR-ABL/ABL and r = 0.98 (P = 0.0004) for the ratios BCR-ABL/G6PD. complete cytogenetic responders may vary by as much as four orders of magnitude. 20 In patients after BMT, rising or persistently high levels of BCR-ABL mRNA can be detected prior to cytogenetic or hematologic relapse. 16, [21] [22] [23] [24] Quantitative PCR data has been used to initiate donor lymphocyte transfusions for treatment of relapse 25 and to monitor its response. 26 The advent of real-time PCR enables the direct measurement of the amount of PCR product during the amplification process and therefore reflects the dynamics of the reaction. Although the final amount of PCR product at the plateau phase usually does not correlate well with the number of starting molecules in the reaction, the time-point (cycle number) at which the fluorescence for a particular sample rises above the background (crossover point or threshold cycle) is a much more accurate indicator of the initial number of PCR targets. Amplification and specific detection of fusion transcripts by real-time PCR is possible by simultaneous amplification and fluorescence melting curve analysis using non-specific labeling by the double strand DNA specific dye SYBR Green I. 27 However, if specific detection and accurate quantification is required, it is necessary to use adjacent fluorescence labeled hybridization probes. Real-time PCR does not require post-PCR sample handling and therefore considerably reduces the risk of contamination. In addition, the possibility of contamination is further reduced by the use of heat labile UDG prior to amplification.
Real-time PCR for the detection and quantification of BCR-ABL transcripts using the TaqMan system with a double fluorescence labeled probe 28, 29 has been described recently. 5, 6 In this study we have developed a related system using fluorescent hybridization probes in the LightCycler. 8, 30 One advantage of this system is the rapid cycling time (Ͻ40 s/cycle) due to amplification being performed in glass capillaries and being driven by forced air heating. This system enables the temperature in each reaction to be changed very rapidly. By minimizing denaturation and annealing times, specificity, speed and yield of the reaction are significantly improved. 8 We have optimized and validated this technique in samples from 120 CML patients. The use of probes matching to ABL exon 3 sequences in combination with appropriate primers allows the detection of all known BCR-ABL variants (for reviews, see Refs 31 and 32), including e1a2, 33 e6a2, 32 c3a2 (e19a2), 34 and BCR-ABL transcripts lacking ABL exon 2 (b2a3 35 or b3a3 36, 37 ). The sensitivity of the single step realtime PCR with hybridization of fluorescent probes is almost as high as standard nested PCR. The reason why the real-time assay is slightly less sensitive is almost certainly due to the fact that we used 2 l of cDNA in the LightCycler, but 5 l of cDNA for standard nested PCR.
To standardize BCR-ABL mRNA levels for variability in RNA and cDNA quality, we amplified transcripts of housekeeping genes as internal controls. Appropriate control sequences should be expressed at similar levels as the target genes in nonresponders, and should be cDNA specific, ie they should span long introns, and pseudogenes in genomic DNA must not exist. [38] [39] [40] [41] We therefore decided to use the amplification of total ABL cDNA sequences between exons a2 and a4. The advantage of using ABL is that the same pair of hybridization probes used to quantify BCR-ABL may be applied. We tested the variability of the ABL quantification by comparing ABL and G6PD transcript levels in samples of different qualities and different levels of BCR-ABL. The levels of ABL and G6PD were significantly correlated and similar results were obtained when either BCR-ABL/ABL or BCR-ABL/G6PD ratios were compared with cytogenetic results. These data suggest that either gene may be used as an internal standard. For individual samples, however, significant differences in the G6PD/ABL ratio are seen occasionally and it remains to be determined which is the most appropriate control gene for use in quantitative RT-PCR analysis.
The reliability of this system has been demonstrated by comparison with an existing method of PCR quantification, nested competitive PCR. Virtually identical results were determined with both methods, with a coefficient of correlation of r = 0.90 (P Ͻ 0.0001). The degree of concordance with metaphase cytogenetics and Southern blot analysis was also high. However, some overlap between the conventional cytogenetic response groups may be explained at least in part by the statistical significance of sampling small numbers of metaphases. 42 Results with PB and BM were concordant in all cases indicating that either tissue may be used for residual disease studies in CML. This result confirms similar data that have previously been described using competitive PCR. 17, 43 We conclude that quantitative real-time PCR with hybridization probes is a rapid, sensitive and reliable method for monitoring CML patients after therapy. The method offers the opportunity to standardize the assay and to develop rigorous standards and controls. It is likely that real-time PCR will enable the quantitative analysis of residual disease to become more widely available, not only for patients with CML but also for other malignancies that are characterized by specific molecular markers.
